---
title: MedTech Case Study
description: A Medical device company with a minor supply chain actor which failed in 2022 sparked a resilience drive.
---

[Skip to content](https://www.attaima.com/medtech-case-study#main-content)

[![attaima-logo](https://www.attaima.com/hubfs/attaima-logo.svg) ![attaima logo](https://www.attaima.com/hubfs/attaima-logo.svg)](https://www.attaima.com?hsLang=en)

[Contact our Team](https://www.attaima.com/contact-attaima?hsLang=en)

- [Home](https://www.attaima.com)
- [Product](https://www.attaima.com/attaima-product)
- [Tech](https://www.attaima.com/attaima-tech)
- [Industries](https://www.attaima.com/industries)
- [About](https://www.attaima.com/about-attaima)
- [FAQ](https://www.attaima.com/attaima-faq)
- [Careers](https://www.attaima.com/attaima-careersx)

##### Case Study

# Medical Device Supply Chain Visibility & Risk Management

#### From Partial Visibility to Full Multi-Tier Supply Chain Control

Mapped multi-tier supplier networks with 100% validated tier 2 accuracy uncovering hidden dependencies and enabling faster, data-driven sourcing decisions.

 

### Client Challenge

#### A global medical device manufacturer needed deeper visibility into its supply chain to maintain supply certainty, manage risk, and meet strict regulatory requirements.

![med-tech-1](https://www.attaima.com/hubfs/med-tech-1.jpg)

Despite having established processes and strong supplier relationships, **visibility was largely limited to tier 1**, creating exposure to:

- Hidden supplier dependencies 
- Geographic and logistics concentration risks 
- Supply disruptions impacting production timelines 
- Increased costs from emergency procurement and expedited logistics

Risk identification was **fragmented and reactive**, making it difficult to anticipate disruptions or demonstrate risk management maturity to stakeholders, regulators, and customers.

#### Scope and Objectives

**Goal:** Improve multi-tier supply chain visibility, identify hidden risks, and enable proactive, data-driven sourcing and resiliency decisions.

**Key Inputs**

- BOMs for four primary products and variants 
- Tier 1 supplier data
- Limited internal site and operational data
- Previous supply chain assessments

 

##### Case Study

## The Approach

 

##### 1. Discover & Visualize

- Ingested BOMs and supplier data to map **tier 1 through tier 4 suppliers and dependencies**
- Inferred production geographies and supply flows across regulated components
- Delivered a live, user-friendly, human-centric interactive canvas of the full value chain

![pharma-cs-1](https://www.attaima.com/hubfs/pharma-cs-1.svg)

 

##### 2. Identify Weak Spots

- Identified **geographic and commercial concentration risks**
- Uncovered **previously unknown long-distance logistics dependencies**
- Detected **inefficiencies and nearshoring reversals**
- Initiated c**ontinuous reputational risk monitoring across suppliers**

![pharma-cs-2-1](https://www.attaima.com/hubfs/pharma-cs-2-1.svg)

 

##### 3. Mitigate

- Surfaced **alternative suppliers and diversification opportunities**
- Enabled **nearshoring and dual-sourcing strategies**
- Provided **enriched supplier intelligence for faster decision-making**

![pharma-cs-3](https://www.attaima.com/hubfs/pharma-cs-3.svg)

 

##### Outcomes

- **100% validation accuracy** at tier 2 supplier level
- Identification of **critical concentration and logistics risks**
- Detection of multiple geographic concentration risks across **critical components**
- Reduction in time to insight from **weeks to days**
- Identification of nearshoring reversals impacting **cost and resilience**
- Strengthened ability to **demonstrate risk maturity to boards and customers**

 

#### **Why Attaima?**

- **Rapid deployment:** Platform operational and delivering insights in days
- **Deep visibility:** Extended beyond tier 1 to uncover hidden risks
- **Actionable intelligence:** Enabled immediate sourcing and mitigation decisions
- **Continuous monitoring:** Identified emerging risks in real time
- **Audit-ready outputs:** Strengthened compliance and reporting

#### **Next steps / ongoing work**

- Expand monitoring across all suppliers and product lines
- Integrate **advanced scenario modelling for proactive risk management**
- Extend insights to support **long-term strategic sourcing decisions**

![med-tech-white](https://www.attaima.com/hubfs/med-tech-white.svg)

> “ We uncovered risks we didn’t know existed and gained the ability to act before they impacted production and our customers. ”

##### — VP Operations

###### Medical Device Manufacturer

## ![Emblem](https://www.attaima.com/hs-fs/hubfs/Emblem.png?width=40&height=37&name=Emblem.png)

## Learn more about how Attaima can help your Medtech value chain

[![attaima-logo](https://www.attaima.com/hubfs/attaima-logo.svg)](https://www.attaima.com?hsLang=en)

- [Terms & Conditions](https://www.attaima.com/attaima-terms-conditions)
- [Privacy Policy](https://www.attaima.com/attaima-privavcy-policy)

© 2026 Attaima | All rights reserved.